Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

MicroRNAs Affect Complement Regulator Expression and Mitochondrial Activity to Modulate Cell Resistance to Complement-Dependent Cytotoxicity.

Hillman Y, Mardamshina M, Pasmanik-Chor M, Ziporen L, Geiger T, Shomron N, Fishelson Z.

Cancer Immunol Res. 2019 Dec;7(12):1970-1983. doi: 10.1158/2326-6066.CIR-18-0818. Epub 2019 Sep 19.

PMID:
31537542
2.

Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.

Rozenberg P, Ziporen L, Gancz D, Saar-Ray M, Fishelson Z.

Cell Death Dis. 2018 Feb 2;9(2):150. doi: 10.1038/s41419-017-0240-z.

3.

Programmed necrotic cell death induced by complement involves a Bid-dependent pathway.

Ziporen L, Donin N, Shmushkovich T, Gross A, Fishelson Z.

J Immunol. 2009 Jan 1;182(1):515-21.

4.

Cell signals transduced by complement.

Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z.

Mol Immunol. 2004 Jul;41(6-7):583-97. Review.

PMID:
15219997
5.

Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model.

Ziporen L, Polak-Charcon S, Korczyn DA, Goldberg I, Afek A, Kopolovic J, Chapman J, Shoenfeld Y.

Clin Dev Immunol. 2004 Mar;11(1):67-75.

6.

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z.

Clin Exp Immunol. 2003 Feb;131(2):254-63.

7.

Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells.

Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, Hiss E, Ziporen L, Aviram M, Cines D, Poncz M, Higazi AA.

J Biol Chem. 2003 Feb 21;278(8):6187-93. Epub 2002 Dec 3.

8.

Antiphospholipid antibodies in a heterogeneous group of patients: experience from a central laboratory.

Mader R, Ziporen L, Mader R, Neumann L, Buskila D.

Clin Rheumatol. 2002 Sep;21(5):386-90.

PMID:
12223987
9.

Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome.

Afek A, Shoenfeld Y, Manor R, Goldberg I, Ziporen L, George J, Polak-Charcon S, Amigo MC, Garcia-Torres R, Segal R, Kopolovic J.

Lupus. 1999;8(7):502-7.

PMID:
10483026
10.

A mouse model for heparin-induced thrombocytopenia.

Blank M, Eldor A, Tavor S, Ziporen L, Cines DB, Arepally G, Afek A, Shoenfeld Y.

Semin Hematol. 1999 Jan;36(1 Suppl 1):12-6.

PMID:
9930558
11.
12.

Lessons from experimental APS models.

Shoenfeld Y, Ziporen L.

Lupus. 1998;7 Suppl 2:S158-61. Review.

PMID:
9814695
13.

Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M.

Blood. 1998 Nov 1;92(9):3250-9.

PMID:
9787161
14.

Anti-endothelial cell antibody binding makes negatively charged phospholipids accessible to antiphospholipid antibodies.

Bordron A, Dueymes M, Levy Y, Jamin C, Ziporen L, Piette JC, Shoenfeld Y, Youinou P.

Arthritis Rheum. 1998 Oct;41(10):1738-47.

PMID:
9778215
15.

Massive proteinuria as a main manifestation of primary antiphospholipid syndrome.

Levy Y, George J, Ziporen L, Cledes J, Amital H, Bar-Dayan Y, Afek A, Youinou P, Shoenfeld Y.

Pathobiology. 1998;66(1):49-52.

PMID:
9577967
16.

Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD.

J Clin Invest. 1997 Aug 1;100(3):613-9.

17.

[Libman-Sacks endocarditis--a jubilee year].

Afek A, Ziporen L, Shoenfeld Y.

Harefuah. 1997 May 15;132(10):718-9. Review. Hebrew. No abstract available.

PMID:
9223803
18.

Animal models for antiphospholipid syndrome in pregnancy.

Ziporen L, Blank M, Shoenfeld Y.

Rheum Dis Clin North Am. 1997 Feb;23(1):99-117. Review.

PMID:
9031377
19.

Do some antiphospholipid antibodies target endothelial cells?

Dueymes M, Levy Y, Ziporen L, Jamin C, Piette JC, Shoenfeld Y, Youinou P.

Ann Med Interne (Paris). 1996 Sep;147 Suppl 1:22-3.

PMID:
8952755
20.

Superantigens and experimental SLE induced by idiotypic dysregulation.

Baharav E, Gur H, Fishman P, Ziporen L, Blank M, Aelion J, Kotb M, Shoenfeld Y.

Clin Exp Rheumatol. 1996 Jul-Aug;14(4):359-66.

PMID:
8871833
21.

Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves.

Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A, Blank M, Sandbank Y, Vilardell-Tarres M, de Torres I, Weinberger A, Asherson RA, Kopolovic Y, Shoenfeld Y.

Lupus. 1996 Jun;5(3):196-205.

PMID:
8803890
22.

Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.

Hojnik M, George J, Ziporen L, Shoenfeld Y.

Circulation. 1996 Apr 15;93(8):1579-87. Review.

PMID:
8608627
23.

Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice.

Levy Y, Ziporen L, Gilburd B, George J, Polak-Charcon S, Amital H, Cledes J, Youinou P, Shoenfeld Y.

Hum Antibodies Hybridomas. 1996;7(3):91-6.

PMID:
9057056
24.

Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy.

Hojnik M, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, Tincani A, Rozman B, Shoenfeld Y.

Lupus. 1994 Dec;3(6):515-21.

PMID:
7704010
25.

Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy.

Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, Guedes LH, Gershwin ME, Shoenfeld Y.

J Clin Immunol. 1994 Jan;14(1):14-9.

PMID:
8132733

Supplemental Content

Loading ...
Support Center